OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.06.

OncoCyte Price Performance

OCX stock opened at $3.10 on Wednesday. OncoCyte has a one year low of $2.08 and a one year high of $4.34. The company’s 50 day moving average price is $3.06 and its two-hundred day moving average price is $2.93.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

Insiders Place Their Bets

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrea S. James purchased 33,670 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief financial officer now directly owns 33,670 shares in the company, valued at $99,999.90. The disclosure for this purchase can be found here. 1.58% of the stock is owned by insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.